keyword
MENU ▼
Read by QxMD icon Read
search

Acute myelogenous leukemia

keyword
https://www.readbyqxmd.com/read/29771146/nanosized-ethanol-based-malleable-liposomes-of-cytarabine-to-accentuate-transdermal-delivery-formulation-optimization-in-vitro-skin-permeation-and-in-vivo-bioavailability
#1
Rakesh Raj, Pooja Mongia Raj, Alpana Ram
Cytarabine is a pyrimidine nucleoside analog used predominantly for acute myeloid leukemia (AML) and also for other indications, including acute lymphocytic leukemia, chronic myelogenous leukemia, and lymphoma by parenteral route due to its low oral bioavailability. Parenteral administration requires constant plasma level, monitoring for its fluctuation and poor patients compliances. Hence the objective of this work is to construct optimized nanosized malleable liposomes of cytarabine to accentuate transdermal delivery of drug to circumvent previously mentioned drawbacks...
May 17, 2018: Artificial Cells, Nanomedicine, and Biotechnology
https://www.readbyqxmd.com/read/29770715/enasidenib-for-the-treatment-of-acute-myeloid-leukemia
#2
James Dugan, Daniel Pollyea
In August 2017 the United States Federal Drug Administration (FDA) approved enasidenib (Idhifa, Celgene/Agios) for adults with relapsed and refractory acute myelogenous leukemia (AML) with an IDH2 mutation. Enasidenib targets cells with mutant copies of isocitrate dehydrogenase-2 (IDH2), inhibiting the oncometabolite 2-hydroxyglutarte (2-HG) formed by the mutant IDH2. Areas covered: We review the studies leading to enasidenib's approval, as well as common side effects and safety issues experienced during the clinical trials...
May 17, 2018: Expert Review of Clinical Pharmacology
https://www.readbyqxmd.com/read/29763550/selective-inhibition-of-the-myeloid-src-family-kinase-fgr-potently-suppresses-aml-cell-growth-in-vitro-and-in-vivo
#3
Mark C Weir, Sherry T Shu, Ravi K Patel, Sabine Hellwig, Li Chen, Li Tan, Nathanael S Gray, Thomas E Smithgall
Acute myelogenous leukemia (AML) is the most common hematologic malignancy in adults, and is often associated with constitutive tyrosine kinase signaling. These pathways involve the non-receptor tyrosine kinases Fes, Syk and the three Src-family kinases expressed in myeloid cells (Fgr, Hck, and Lyn). In this study, we report remarkable anti-AML efficacy of an N-phenylbenzamide kinase inhibitor, TL02-59. This compound potently suppressed the proliferation of bone marrow samples from twenty of twenty-six AML patients, with a striking correlation between inhibitor sensitivity and expression levels of the myeloid Src family kinases Fgr, Hck, and Lyn...
May 15, 2018: ACS Chemical Biology
https://www.readbyqxmd.com/read/29762824/long-noncoding-rna-uca1-promotes-cell-proliferation-migration-and-invasion-of-human-leukemia-cells-via-sponging-mir-126
#4
M-D Sun, Y-Q Zheng, L-P Wang, H-T Zhao, S Yang
OBJECTIVE: Acute myeloid leukemia (AML) is a bone marrow malignancy. Long non-coding RNA (lncRNA) urothelial carcinoma-associated 1 (UCA1) plays an important role in several cancers. However, the role of lncRNA UCA1 in AML remained unclear. MATERIALS AND METHODS: LncRNA UCA1 expressions in different cell lines were determined by RT-PCR. In human myelogenous leukemia (ML) cell lines K562 and HL60, effects of lncRNA UCA1 knockdown on cell viability, migration, invasion, and apoptosis were assessed, respectively...
April 2018: European Review for Medical and Pharmacological Sciences
https://www.readbyqxmd.com/read/29757653/metabolism-of-an-oxime-linked-antibody-drug-conjugate-ags62p1-and-characterization-of-its-identified-metabolite
#5
Josh T Snyder, Maria-Christina Malinao, Julien Dugal-Tessier, John E Atkinson, Banmeet S Anand, Akihiro Okada, Brian A Mendelsohn
AGS62P1 is an antibody drug conjugate (ADC) composed of a human IgG1κ monoclonal antibody against FLT3 (FMS-like tyrosine kinase 3) with a p-acetyl phenylalanine (pAF) residue inserted at position 124 of each heavy chain linked to the proprietary microtubule disrupting agent AGL-0182-30 via an alkoxyamine linker that forms an oxime upon conjugation to the antibody. AGS62P1 is currently in Phase I human clinical trials for acute myelogenous leukemia (AML). The identified primary metabolite of an oxime-linked ADC is presented for the first time...
May 14, 2018: Molecular Pharmaceutics
https://www.readbyqxmd.com/read/29752319/misdiagnosis-of-li-fraumeni-syndrome-in-a-patient-with-clonal-hematopoiesis-and-a-somatic-tp53-mutation
#6
Rachel L Mitchell, Cory Kosche, Kelly Burgess, Shreya Wadhwa, Lela Buckingham, Ritu Ghai, Jacob Rotmensch, Oleksandra Klapko, Lydia Usha
Li-Fraumeni syndrome (LFS) is a rare genetic disorder that confers a high risk of developing certain malignancies at a young age. It is caused by germline mutations in the TP53 gene and is typically diagnosed by sequencing this gene in blood cells. The presence of a mutation in approximately half of the DNA reads (allelic fraction of 50%) is an indicator of a germline mutation, such as that in LFS. Clonal hematopoiesis (CH) is an expansion of a hematopoietic clone containing a somatic driver mutation with a low allelic fraction, usually not more than 10% to 20%...
May 2018: Journal of the National Comprehensive Cancer Network: JNCCN
https://www.readbyqxmd.com/read/29734213/clinical-and-radiographic-response-of-extramedullary-leukemia-in-patients-treated-with-gemtuzumab-ozogamicin
#7
Michael J McNeil, Marguerite T Parisi, Nobuko Hijiya, Soheil Meshinchi, Todd Cooper, Katherine Tarlock
Extramedullary leukemia (EML) is common in pediatric acute leukemia and can present at diagnosis or relapse. CD33 is detected on the surface of myeloid blasts in many patients with acute myelogenous leukemia and is the target of the antibody drug conjugate gemtuzumab ozogamicin (GO). Here we present 2 patients with CD33 EML treated with GO. They achieved significant response, with reduction of EML on both clinical and radiographic exams, specifically fluorine fluorodeoxyglucose positron emission tomography/computed tomography, demonstrating potential for targeted therapy with GO as a means of treating EML in patients with CD33 leukemia and the utility of fluorine fluorodeoxyglucose positron emission tomography/computed tomography monitoring in EML...
May 4, 2018: Journal of Pediatric Hematology/oncology
https://www.readbyqxmd.com/read/29723350/clinical-and-pathological-features-of-myeloid-leukemia-cutis
#8
Li Li, Yanan Wang, Christine Guo Lian, Nina Hu, Hongzhong Jin, Yuehua Liu
BACKGROUND: Myeloid leukemia cutis is the terminology used for cutaneous manifestations of myeloid leukemia. OBJECTIVE: The purpose of this study was to study the clinical, histopathological and immunohistochemical features of myeloid leukemia cutis. METHODS: This was a retrospective study of clinical and pathological features of 10 patients with myeloid leukemia cutis. RESULTS: One patient developed skin lesions before the onset of leukemia, seven patients developed skin infiltration within 4-72 months after the onset of leukemia, and two patients developed skin lesions and systemic leukemia simultaneously...
March 2018: Anais Brasileiros de Dermatologia
https://www.readbyqxmd.com/read/29713555/-bacillus-cereus-typhlitis-in-a-patient-with-acute-myelogenous-leukemia-a-case-report-and-review-of-the-literature
#9
James D Denham, Sowmya Nanjappa, John N Greene
Bacillus cereus is a Gram-positive rod that is now recognized as a rare cause of frank disease in the neutropenic hematologic malignancy patient. Because this pathogen is rarely isolated in clinical specimens, no large studies exist to guide the management of these acutely ill patients. Individual case reports and case series exist in the literature describing various clinical manifestations of B. cereus in the neutropenic patient including bacteremia/septicemia, pneumonia, meningitis/encephalitis, hepatic abscesses, and gastritis...
2018: Case Reports in Infectious Diseases
https://www.readbyqxmd.com/read/29693737/how-to-prophylax-against-invasive-fungal-infections-in-adult-all-an-unmet-need
#10
Oliver A Cornely, Dimitrios P Kontoyiannis
Although the benefit for any type of antifungal prophylaxis in patients with acute myelogenous leukemia is well accepted, less is known about the risk for invasive fungal infections (IFIs) and the optimal prophylaxis strategies in patients with acute lymphocytic leukemia (ALL). Based on recent studies, ALL is a disease that appears to be associated with significant risk for IFIs. The pharmacokinetic interactions between azoles and vincristine, an antineoplastic agent that is part of modern combination chemotherapies in ALL, results in clinically significant neurotoxicity that makes the use of azoles problematic...
April 25, 2018: Mycoses
https://www.readbyqxmd.com/read/29692408/the-basic-helix-loop-helix-transcription-factor-sharp1-is-an-oncogenic-driver-in-mll-af6-acute-myelogenous-leukemia
#11
Akihiko Numata, Hui Si Kwok, Akira Kawasaki, Jia Li, Qi-Ling Zhou, Jon Kerry, Touati Benoukraf, Deepak Bararia, Feng Li, Erica Ballabio, Marta Tapia, Aniruddha J Deshpande, Robert S Welner, Ruud Delwel, Henry Yang, Thomas A Milne, Reshma Taneja, Daniel G Tenen
Acute Myeloid Leukemia (AML) with MLL gene rearrangements demonstrate unique gene expression profiles driven by MLL-fusion proteins. Here, we identify the circadian clock transcription factor SHARP1 as a novel oncogenic target in MLL-AF6 AML, which has the worst prognosis among all subtypes of MLL-rearranged AMLs. SHARP1 is expressed solely in MLL-AF6 AML, and its expression is regulated directly by MLL-AF6/DOT1L. Suppression of SHARP1 induces robust apoptosis of human MLL-AF6 AML cells. Genetic deletion in mice delays the development of leukemia and attenuated leukemia-initiating potential, while sparing normal hematopoiesis...
April 24, 2018: Nature Communications
https://www.readbyqxmd.com/read/29667722/acute-myelogenous-leukemia-in-adolescents-and-young-adults
#12
REVIEW
Ursula Creutzig, Matthew A Kutny, Ronald Barr, Richard F Schlenk, Raul C Ribeiro
The incidence of acute myelogenous leukemia (AML) increases progressively with age. Favorable genetic mutations are most prevalent in children, and unfavorable profiles increase proportionately in adolescents and young adults (AYA) and into later adulthood. Survival rates of AYA have improved over recent decades to 50-60%, but their accrual to clinical trials remains poor. In contrast to AYA with acute lymphoblastic leukemia, the prognostic benefit for AYA with AML enrolled in pediatric compared with adult trials is minor and only seen when different protocols are used...
April 18, 2018: Pediatric Blood & Cancer
https://www.readbyqxmd.com/read/29645075/results-of-second-salvage-therapy-in-673-adults-with-acute-myelogenous-leukemia-treated-at-a-single-institution-since-2000
#13
Hagop M Kantarjian, Courtney D DiNardo, Graciela M Nogueras-Gonzalez, Tapan M Kadia, Elias Jabbour, Carlos E Bueso-Ramos, Susan M O'Brien, Marina Konopleva, Nitin B Jain, Naval G Daver, Elizabeth J Shpall, Richard E Champlin, Aron Simkins, Guillermo Garcia-Manero, Michael J Keating, Xuelin Huang, Jorge E Cortes, Sherry A Pierce, Farhad Ravandi, Emil J Freireich
BACKGROUND: The prognosis is poor for patients who have relapsed-refractory acute myelogenous leukemia (AML). Most published reports analyzed results from therapies in first-salvage AML or in studies that were conducted before 2000. Several novel agents and strategies are being tested for potential approval as treatment for patients with relapsed-refractory AML in second salvage. Therefore, it is important to establish the historic results of anti-AML therapies in this setting in the modern era...
April 12, 2018: Cancer
https://www.readbyqxmd.com/read/29644709/optimizing-the-pretransplant-regimen-for-autologous-stem-cell-transplantation-in-acute-myelogenous-leukemia-better-outcomes-with-busulfan-and-melphalan-compared-with-busulfan-and-cyclophosphamide-in-high-risk-patients-autografted-in-first-complete-remission
#14
Norbert Claude Gorin, Myriam Labopin, Didier Blaise, Pierre-Yves Dumas, Thomas Pabst, Silvia Maria Trisolini, William Arcese, Mohamed Houhou, Mohamad Mohty, Arnon Nagler
Autologous stem cell transplantation (ASCT) remains a clinical option to consolidate some adult patients with acute myelogenous leukemia (AML) in first complete remission (CR1). In a small cohort of patients, we have previously shown better outcomes following Busulfan and Melphalan (BUMEL) over Busulfan and Cyclophosphamide (BUCY). To identify the subpopulations that might get the highest benefit with BUMEL, we designed a larger study. All adult patients with primary AML and available cytogenetics, autografted from January 2000 to December 2016 in CR1, were included: 1137 patients received BUCY and 512 BUMEL...
April 12, 2018: American Journal of Hematology
https://www.readbyqxmd.com/read/29619260/bilateral-conjunctival-infiltration-as-an-extramedullary-relapse-of-aml
#15
Zahra Mozaheb, Alireza Khooei
Acute myelogenous leukemia (AML) accounts for 1.2% of all cancer deaths. Relapse is the major cause of treatment failure in acute myeloid leukemia (AML) patients. AML rarely presents as ocular manifestation in relapse or at presentation. The M4 subtype of AML is most commonly presented with extramedullary involvement. In this report, we presented a young female with AML who was diagnosed and treated for AML about 40 months ago. She did not transplant because she did not have a full-match donor. About 4 months ago, she visited with a red eye and conjunctival infiltration...
2018: Case Reports in Hematology
https://www.readbyqxmd.com/read/29616908/glioblastoma-multiforme-in-a-patient-with-multiple-myeloma-a-case-report-and-literature-review
#16
Christine A Moore, Moayed Ibrahim, Aaysha Kapila, Kailash Bajaj
INTRODUCTION: Lenalidomide is an immunomodulatory drug approved by the US Food and Drug Administration in 2006 for the treatment of multiple myeloma. In 2012, the Food and Drug Administration issued a statement warning physicians of the increased risk with lenalidomide treatment of the following secondary primary malignancies: Acute myelogenous leukemia, myelodysplastic syndromes, and Hodgkin lymphoma. The statement did not mention glioblastoma multiforme, a Grade 4 astrocytoma, or other high-grade astrocytomas that have been reported on rare occasions in the setting of multiple myeloma...
March 30, 2018: Permanente Journal
https://www.readbyqxmd.com/read/29616870/the-influence-of-lymphoid-reconstitution-kinetics-on-clinical-outcomes-in-allogeneic-stem-cell-transplantation
#17
David J Kobulnicky, Roy T Sabo, Shashank Sharma, Ali S Shubar Ali, Kristen M Kobulnicky, Catherine H Roberts, William B Clark, Harold M Chung, John M McCarty, Amir A Toor
Lymphoid recovery following myeloablative stem cell transplantation (SCT) displays a logistic pattern of exponential growth followed by a plateau. Within this logistic framework, lymphoid recovery is characterized by the parameters R (slope of ascent), a (time of maximal rate of ascent) and K (plateau), the 'steady-state' lymphocyte count. A retrospective analysis of allogeneic SCT performed from 2008 to 2013 was undertaken to compare lymphoid recovery and clinical outcomes in 131 patients with acute myelogenous leukemia, acute lymphocytic leukemia, and myelodysplastic syndromes...
April 4, 2018: Leukemia & Lymphoma
https://www.readbyqxmd.com/read/29607465/sirolimus-enhances-remission-induction-in-patients-with-high-risk-acute-myeloid-leukemia-and-mtorc1-target-inhibition
#18
Margaret T Kasner, Rosemarie Mick, Grace R Jeschke, Matthew Carabasi, Joanne Filicko-O'Hara, Neal Flomenberg, Noelle V Frey, Elizabeth O Hexner, Selina M Luger, Alison W Loren, James K Mangan, John L Wagner, Mark Weiss, Martin Carroll, Alexander E Perl
Background Mammalian Target of Rapamycin Complex 1 (mTORC1) inhibitors enhance chemotherapy response in acute myelogenous leukemia (AML) cells in vitro. However whether inhibiting mTORC1 enhances clinical response to AML chemotherapy remains controversial. We previously optimized measurement of mTORC1's kinase activity in AML blasts during clinical trials using serial phospho-specific flow cytometry of formaldehyde-fixed whole blood or marrow specimens. To validate mTORC1 as a therapeutic target in AML, we performed two clinical trials combining an mTORC1 inhibitor (sirolimus) and MEC (mitoxantrone, etoposide, cytarabine) in patients with relapsed, refractory, or untreated high-risk AML...
April 2, 2018: Investigational New Drugs
https://www.readbyqxmd.com/read/29594316/an-integrated-approach-to-elucidate-signaling-pathways-of-dioscin-induced-apoptosis-energy-metabolism-and-differentiation-in-acute-myeloid-leukemia
#19
She-Hung Chan, Pi-Hui Liang, Jih-Hwa Guh
Although the therapeutics have improved the rates of remission and cure of acute myelogenous leukemia (AML) in recent decades, there is still an unmet medical need for AML therapies because disease relapses are a major obstacle in patients who become refractory to salvage therapy. The development of therapeutic agents promoting both cytotoxicity and cell differentiation may provide opportunities to improve the clinical outcome. Dioscin-induced apoptosis in leukemic cells was identified through death receptor-mediated extrinsic apoptosis pathway...
March 28, 2018: Naunyn-Schmiedeberg's Archives of Pharmacology
https://www.readbyqxmd.com/read/29589969/checkpoint-inhibitors-and-acute-myelogenous-leukemia-promises-and-challenges
#20
Mansour Alfayez, Gautam Borthakur
Immunity, for treatment of acute myelogenous leukemia (AML), has been leveraged historically in the form of allogeneic stem cell transplantation. Checkpoint inhibitors (CPI) as positive modulators of immune response have been recent major breakthroughs in solid tumors. Areas covered: Emerging concepts and clinical data with CPIs in AML - the focus of this review - will be discussed. CPIs can potentially be effective in absence of 'actionable' mutations and are expected to be effective against poor-risk AML...
March 28, 2018: Expert Review of Hematology
keyword
keyword
17969
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"